Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Continuous Delivery of Levodopa/Carbidopa Using the Intra-Oral DopaFuse System: A Safety, Tolerability, PK and Efficacy Trial
Movement Disorders
ES2 - Emerging Science 2 (5:48 PM-5:54 PM)
004

It is well-established that continuous delivery of levodopa/carbidopa (LD/CD) is associated with significant improvement in ON time without troublesome dyskinesia and OFF time in advanced PD patients. The DopaFuse system attaches to a retainer and uses a propellant to deliver LD/CD continuously into the mouth, thereby avoiding the need for surgical procedures, cumbersome pumps, and the development of infusion site reactions. 

Assess the safety, PK, and efficacy of levodopa/carbidopa (LD/CD) delivered continuously by an intra-oral micropump (DopaFuse) compared with standard oral LD/CD.

16 patients participated in a 2-week, open-label trial. Patients were treated in clinic as follows: Day-1, usual dose of standard LD/CD; Day-2, continuous delivery of LD/CD with DopaFuse; Day-3, continuous delivery of LD/CD with DopaFuse after a single morning dose of standard LD/CD. Patients were sent home on Days 4-14 and treated with the same regimen as Day-3, and returned to clinic on Day-15. Levodopa PK was measured at 30-60min intervals for 12h on Days 1, 2, and 3. Motor state was evaluated at 30-min intervals for 12h on Days 1, 3, and 15.

In comparison to standard LD/CD treatment (day1), continuous intra-oral delivery was associated with significantly less variability in plasma levodopa as determined by fluctuation index (P=0.01 and P<0.001 on Day- 2 and Day-3 respectively) and Coefficient of Variation (P=0.02 and P<0.001 on Day-2 and Day-3 respectively). ON time without severe dyskinesia and OFF time on Day-3 and -15 each significantly improved with DopaFuse (P<0.001) as was UPDRS-part II at Day-15 (P=0.016). There were no dropouts and no clinically significant adverse events. 

Continuous delivery of LD/CD using the DopaFuse System was well tolerated. DopaFuse was associated with significantly less variability in plasma levodopa and significant improvement in measures of motor function and ADLs in comparison to treatment with standard intermittent LD/CD. 

Authors/Disclosures
C. Warren Olanow, MD
PRESENTER
Dr. Olanow has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Chevron/Syngenta. Dr. Olanow has stock in Clintrex Research Corporation.
Deborah J. McIntyre, MD (Dr Deborah McIntyre) Dr. McIntyre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck & Roche pharmaceuticals. Dr. McIntyre has received personal compensation in the range of $50,000-$99,999 for serving as a employed physician scientist with Luxembourg Institute of Health.
Michele Matarazzo, MD (HM CINAC) Dr. Matarazzo has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International Parkinson and Movement Disorders Society.
Rejko Krueger Rejko Krueger has nothing to disclose.
Jose A. Obeso, MD (CINAC ) No disclosure on file
Andrew J. McGarry, MD (Cooper University Hospital) Dr. McGarry has nothing to disclose.
Fabrizio Stocchi Fabrizio Stocchi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bial, Biogen, Sunovion, Lundbeck, UCB, Zambon, Chiesi, Lusofarmaco, Abbvie, Neuroderm, Kyowa, Synegile, Roche, Britannia, Sunovion, Blue Rock. Fabrizio Stocchi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL, Zambon, Biogen, Roche, Synegile, Sunovion. Fabrizio Stocchi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bial, Zambon, UCB, Kyowa, Sunovion.